Compartmental analysis of the pharmacokinetics of radioiodinated monoclonal antibody B72.3 in colon cancer patients.
Sixteen patients with colorectal cancer were administered 37-74 MBq (1 mg) of radioiodinated B72.3 monoclonal antibody. Pharmacokinetic analysis was carried out on plasma and urine samples. Elimination from the plasma was biexponential with a mean T1/2 alpha of 3.7 h and T1/2 beta of 62.4 h. The plasma clearance was fit to a two-compartmental model. This was combined with a previously reported model for radioiodine to construct a composite model. There was a good correlation (r = 0.952) between the model-predicted and observed excretion of radioiodine suggesting that the composite model is compatible with the pharmacokinetics of the radiolabelled antibody.
Reilly
R M
RM
Division of Nuclear Medicine, Toronto Hospital, Ontario, Canada.
Kirsh
J
J
Gallinger
S
S
Thiessen
J J
JJ
Damani
M
M
Hay
K
K
Polihronis
J
J
Schmocker
B
B
Odze
R
R
Houle
S
S
D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D003110:Colonic Neoplasms / Q000097:blood / Q000378:metabolism* / Q000652:urine; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D051379:Mice; D008875:Middle Aged; D008956:Models, Chemical; D011829:Radiation Dosage
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes